As another key step towards its planned public listing, neurocare is very pleased to announce the closing of a significant financing round with its existing anchor investor bm|t and new strategic investor re.Mind, the mental health fund of Apeiron, the family office of Christian Angermayer, a prolific investor in life sciences and mental health, among other sectors.
neurocare is grateful to bm|t for participating in this financing and believes that re.Mind is a value-enhancing strategic investor for neurocare. Apeiron have a proven track record of financing innovaton in the emerging psychedelics space. This access to more pschedelics is a complement to neurocare who already collaborates with physicians applying ketamine.
Kevin Reeder, CEO of bm|t said: “We are pleased to see neurocare strengthening its position for its much-needed innovative approach in mental health, especially once the world is looking beyond the actual pandemic to the collateral damage in mental health. The endorsement of a strategic investor with such an impressive track record is an extremely strong affirmation that neurocare is a best-in-class provider of personalized mental health solutions”.
Christian Angermayer says: “The concept of neurocare represents the blueprint for future mental care: they apply a range of strongly evidenced therapeutics tailored to the individual. Whether it’s neuromodulation, traditional CBT or indeed psychedelic medicines, neurocare delivers world-class personalized care.” Jan Hardorp, Partner of re.Mind says, “neurocare has an innovative model of care that can also be out-licensed around the world. They are growing rapidly, with a superior economic model to what we’ve seen elsewhere. We join neurocare so that more patients can access solutions befitting the complex nature of mental health. We are proud to become an anchor investor in neurocare and drive synergies with Apeiron’s portfolio of companies.”
Alex Zobel, neurocare’s CFO and Tom Mechtersheimer, Founder and CEO of neurocare said: “We are excited because the strategic fit is very good and we can expand our footprint for the demand expected post pandemic. In recent years we have been integrating neuromodulation into best clinical practice through our DTx platform and with our new partners we will launch more psychedelics. This funding will allow us to accelerate towards the public markets and global scaling. We are grateful to our existing investors and welcome our new shareholders warmly.”
neurocare is innovating mental health and performance and developed a digital therapeutics (DTx) platform empowering clinicians to deliver best practice. Following a detailed assessment, clinicians develop personalised therapy plans that lead to best evidence-based outcomes. neurocare’s objective and measurable approach is based on our brain’s natural ability to learn (neuroplasticity) adding technology to enhance that learning and care delivery. Since this approach enables individuals to regain their self-regulation it is a sustainable solution with very few side effects not merely symptom management.
About re.Mind and Apeiron
re.Mind Capital is a venture capital fund founded by Christian Angermayer, together with partners Jan Hardorp and Max de Vere. Angermayer is best known for his pioneering investments into psychedelics, and is a co-founder for Atai Life Sciences and Compass Pathways, which today is listed on the NASDAQ. re.Mind invests into companies at any stage, which are creating radical new solutions in mental health and neuroscience. In 2020, Angermayer was the key driver behind IPOs and major fundraisings of Compass Pathways, AbCellerea and Sensei Biotherapeutics.
Erfurt-based, beteiligungsmanagement thüringen (bm|t) — a subsidiary of the Thüringen Development Bank, is a the first address for investments in Thüringen, Germany. bm|t currently manages ten investment funds with a total volume of 440M EUR. bm|t invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.